Children with relapsing multiple sclerosis (MS) had an 82% lower relapse rate when treated with a drug currently only licensed for use in adults.

The Irish arm of pharma giant Novartis last year increased its profits by 31% on the back on strong performance by a number of brands.

Hundreds of patients are being denied fast access to vital stroke, multiple sclerosis, bipolar disorder and hepatitis C drugs because the HSE is “rationing” money for new treatments.